Cannabinoid receptor 2: a potential novel therapeutic target for sepsis?

References

• American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20(6):864–874.
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810.10.1001/jama.2016.0287
   PubMed Web of Science ®Google Scholar
• Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014;5(1):4–11.10.4161/viru.27372
   PubMed Web of Science ®Google Scholar
• Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546–1554.10.1056/NEJMoa022139
   PubMed Web of Science ®Google Scholar
• Kumar G, Kumar N, Taneja A, et al. Nationwide trends of severe sepsis in the 21st century (2000-2007). Chest. 2011;140(5):1223–1231.10.1378/chest.11-0352
   PubMed Web of Science ®Google Scholar
• Gaieski DF, Edwards JM, Kallan MJ, et al. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41(5):1167–1174.10.1097/CCM.0b013e31827c09f8
   PubMed Web of Science ®Google Scholar
• Yebenes JC, Ruiz-Rodriguez JC, Ferrer R, et al. Epidemiology of sepsis in Catalonia: analysis of incidence and outcomes in a European setting. Ann Intensive Care. 2017;7(1):19.10.1186/s13613-017-0241-1
   PubMedGoogle Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–377.10.1007/s00134-017-4683-6
   PubMed Web of Science ®Google Scholar
• Iwashyna TJ, Ely EW, Smith DM, et al. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304(16):1787–1794.10.1001/jama.2010.1553
   PubMed Web of Science ®Google Scholar
• Calandra T, Baumgartner JD, Grau GE, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. Swiss-Dutch J5 Immunoglobulin Study Group. J Infect Dis. 1990;161(5):982–987.10.1093/infdis/161.5.982
   PubMed Web of Science ®Google Scholar
• Calandra T, Gerain J, Heumann D, et al. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med. 1991;91(1):23–29.10.1016/0002-9343(91)90069-A
   PubMed Web of Science ®Google Scholar
• Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996;24(7):1125–1128.10.1097/00003246-199607000-00010
   PubMed Web of Science ®Google Scholar
• Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock. 2001;16(2):83–96.10.1097/00024382-200116020-00001
   PubMed Web of Science ®Google Scholar
• Tamayo E, Fernandez A, Almansa R, et al. Pro- and anti-inflammatory responses are regulated simultaneously from the first moments of septic shock. Eur Cytokine Netw. 2011;22(2):82–87.
   PubMed Web of Science ®Google Scholar
• Novotny AR, Reim D, Assfalg V, et al. Mixed antagonist response and sepsis severity-dependent dysbalance of pro- and anti-inflammatory responses at the onset of postoperative sepsis. Immunobiology. 2012;217(6):616–621.10.1016/j.imbio.2011.10.019
   PubMed Web of Science ®Google Scholar
• Osuchowski MF, Craciun F, Weixelbaumer KM, et al. Sepsis chronically in MARS: systemic cytokine responses are always mixed regardless of the outcome, magnitude, or phase of sepsis. J Immunol. 2012;189(9):4648–4656.10.4049/jimmunol.1201806
   PubMed Web of Science ®Google Scholar
• Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, et al. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev. 2013;93(3):1247–1288.10.1152/physrev.00037.2012
   PubMed Web of Science ®Google Scholar
• van der Poll T, van de Veerdonk FL, Scicluna BP, et al. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17(7):407–420.10.1038/nri.2017.36
   PubMed Web of Science ®Google Scholar
• Han S, Thatte J, Buzard DJ, et al. Therapeutic utility of cannabinoid receptor type 2 (CB 2 ) selective agonists. J Med Chem. 2013;56(21):8224–8256.10.1021/jm4005626
   PubMed Web of Science ®Google Scholar
• Aso E, Ferrer I. CB2 cannabinoid receptor as potential target against alzheimer’s disease. Front Neurosci. 2016;10:243.
   PubMed Web of Science ®Google Scholar
• Malfitano AM, Basu S, Maresz K, et al. What we know and do not know about the cannabinoid receptor 2 (CB2). Semin Immunol. 2014;26(5):369–379.10.1016/j.smim.2014.04.002
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–65.10.1038/365061a0
   PubMed Web of Science ®Google Scholar
• Picone RP, Kendall DA. Minireview: from the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation. Mol Endocrinol. 2015;29(6):801–813.10.1210/me.2015-1062
   PubMed Web of Science ®Google Scholar
• Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5(5):400–411.10.1038/nri1602
   PubMed Web of Science ®Google Scholar
• Borner C, Smida M, Hollt V, et al. Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem. 2009;284(51):35450–35460.10.1074/jbc.M109.006338
   PubMed Web of Science ®Google Scholar
• Rom S, Persidsky Y. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation. J Neuroimmune Pharmacol. 2013;8(3):608–620.10.1007/s11481-013-9445-9
   PubMed Web of Science ®Google Scholar
• Lehmann C, Kianian M, Zhou J, et al. Cannabinoid receptor 2 activation reduces intestinal leukocyte recruitment and systemic inflammatory mediator release in acute experimental sepsis. Crit Care. 2012;16(2):R47.10.1186/cc11248
   PubMed Web of Science ®Google Scholar
• Tschop J, Kasten KR, Nogueiras R, et al. The cannabinoid receptor 2 is critical for the host response to sepsis. J Immunol. 2009;183(1):499–505.10.4049/jimmunol.0900203
   PubMed Web of Science ®Google Scholar
• Gui H, Sun Y, Luo ZM, et al Cannabinoid receptor 2 protects against acute experimental sepsis in mice. Mediators Inflamm. 2013;2013:741303.
   PubMedGoogle Scholar
• Csoka B, Nemeth ZH, Mukhopadhyay P, et al. CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. PLoS One. 2009;4(7):e6409.10.1371/journal.pone.0006409
   PubMed Web of Science ®Google Scholar
• Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728–741.10.1016/j.cell.2011.10.026
   PubMed Web of Science ®Google Scholar
• Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol. 2013;13(10):722–737.10.1038/nri3532
   PubMed Web of Science ®Google Scholar
• Ghanta S, Tsoyi K, Liu X, et al. Mesenchymal stromal cells deficient in autophagy proteins are susceptible to oxidative injury and mitochondrial dysfunction. Am J Respir Cell Mol Biol. 2017;56(3):300–309.10.1165/rcmb.2016-0061OC
   PubMed Web of Science ®Google Scholar
• Liu F, Nie C, Zhao N, et al. MiR-155 alleviates septic lung injury by inducing autophagy via inhibition of transforming growth factor-β-activated binding protein 2. Shock. 2017;48(1):61–68.10.1097/SHK.0000000000000839
   PubMed Web of Science ®Google Scholar
• Pu Q, Gan C, Li R, et al. Atg7 deficiency intensifies inflammasome activation and pyroptosis in pseudomonas sepsis. J Immunol. 2017;198(8):3205–3213.10.4049/jimmunol.1601196
   PubMed Web of Science ®Google Scholar
• Yen YT, Yang HR, Lo HC, et al. Enhancing autophagy with activated protein C and rapamycin protects against sepsis-induced acute lung injury. Surgery. 2013;153(5):689–698.10.1016/j.surg.2012.11.021
   PubMed Web of Science ®Google Scholar
• Shao BZ, Wei W, Ke P, et al Activating cannabinoid receptor 2 alleviates pathogenesis of experimental autoimmune encephalomyelitis via activation of autophagy and inhibiting NLRP3 inflammasome. CNS Neurosci Ther. 2014;20(12):1021–1028.10.1111/cns.2014.20.issue-12
   PubMed Web of Science ®Google Scholar
• Ke P, Shao BZ, Xu ZQ, et al. Activation of cannabinoid receptor 2 ameliorates DSS-induced colitis through inhibiting NLRP3 inflammasome in macrophages. PLoS One. 2016;11(9):e0155076.10.1371/journal.pone.0155076
   PubMed Web of Science ®Google Scholar
• Hiebel C, Behl C. The complex modulation of lysosomal degradation pathways by cannabinoid receptors 1 and 2. Life Sci. 2015;138:3–7.10.1016/j.lfs.2015.03.020
   PubMed Web of Science ®Google Scholar